Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial. A total of 66 subjects with type 2 dia...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2013-01, Vol.2013 (2013), p.1-11
Main Authors: Movahed, Ali, Nabipour, Iraj, Lieben Louis, Xavier, Thandapilly, Sijo Joseph, Yu, Liping, Kalantar Hormozi, Mohammadreza, Rekabpour, Seyed Javad, Netticadan, Thomas
Format: Article
Language:English
Subjects:
Antidiabetics
Blood glucose
Blood pressure
Body weight
Cardiovascular disease
Cholesterol
Clinical trials
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Fasting
Glucose
Hemoglobin
High density lipoprotein
Insulin
Insulin resistance
Kidneys
Liver
Low density lipoprotein
Patients
Resveratrol
Supplements
Tablets
Triglycerides
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial. A total of 66 subjects with type 2 diabetes were enrolled in this study and randomly assigned to intervention group which was supplemented with resveratrol at a dose 1 g/day for 45 days and control group which received placebo tablets. Body weight, blood pressure, fasting blood glucose, haemoglobin A1c, insulin, homeostatic assessments for insulin resistance, triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, and markers of liver and kidney damage were measured at baseline and after 45 days of resveratrol or placebo supplementation. Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels. On the other hand, the placebo group had slightly increased fasting glucose and LDL when compared to their baseline levels. Liver and kidney function markers were unchanged in the intervention group. Overall, this study showed that resveratrol supplementation exerted strong antidiabetic effects in patients with type 2 diabetes.
ISSN:1741-427X
1741-4288
DOI:10.1155/2013/851267